glp-1 and liver cirrhosis The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Current Status of Glucagon-like Peptide-1

It is a calorie-dense food but also nutrient-dense with the majority of its fat being monounsaturated

Beyond glucose control, GLP-1 drugs also act on the brains appetite centers to reduce hunger and promote feelings of fullness

blood pressure remains controlled Medication Tolerability: Occasional early satiety reported, but no severe adverse events One-Year Visit Weight: Down 9 kg overall (BMI 31 kg/m), approaching his target of losing 1012 kg HbA1c: 6.9%, well within the personalized target range set by his endocrinologist Lifestyle: Continues brisk walking 34 times weekly and has enrolled in a weight management support group Quality of Life: Richard reports feeling more energetic, with fewer episodes of low blood sugar after the sulfonylurea dose adjustment Discussion and Alignment with Research Findings Long-Term Projection: Based on modeling data similar to the CORE diabetes model, semaglutide may offer substantial long-term benefits, including reduced risk of cardiovascular complications and improved survival (17)(18)

12 , e34 (2010)